Melanotan II news and clinical trials
Also known as: MT-2 · MT2 · MT-II · Melanotan 2 · MT 2
Updated 49 sources
1 trial update and 3 new studies in the last 12 months, newest first: trial registrations and results, PubMed papers, FDA actions and press coverage that name Melanotan II. Each line links to the primary source.
October 2026
- StudyPubMedPeptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review (opens PubMed)
A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.
Sexual medicine reviewsReviewPMID 42862021
September 2026
- StudyPubMedDangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs (opens PubMed)
New review in Missouri medicine: Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Missouri medicineReviewPMID 42757290
February 2026
- New trialClinicalTrials.govMelanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo (opens ClinicalTrials.gov)
Hudson Biotech registered a Phase 2, randomized, double-blind study to evaluate the use of Melanotan II as an adjunct to narrowband UV-B phototherapy in 60 adults with stable nonsegmental vitiligo.
NCT07437560Phase 2recruiting - StudyPubMedChanges in Oral Mucosa Associated with Melanotan II Injections: A Case Report (opens PubMed)
Researchers reported a case of a patient who developed brown pigmentation on the gums and mouth after self-administering Melanotan II for 64 days. While buccal mucosal pigmentation faded after discontinuation, gingival pigmentation persisted for three months.
Life (Basel, Switzerland)Case reportPMID 41752902
Searched as: Melanotan II, Melanotan 2. Summaries are one or two sentences, published only when every number in them appears in the source record. A tracker, not medical advice.